A pathway of structural changes produced by monastrol binding to Eg5

Zoltan Maliga, Jun Xing, Herbert Cheung, Laura J. Juszczak, Joel M. Friedman, Steven Rosenfeld

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Monastrol is a small molecule inhibitor that is specific for Eg5, a member of the kinesin 5 family of mitotic motors. Crystallographic models of Eg5 in the presence and absence of monastrol revealed that drug binding produces a variety of structural changes in the motor, including in loop L5 and the neck linker. What is not clear from static crystallographic models, however, is the sequence of structural changes produced by drug binding. Furthermore, because crystallographic structures can be influenced by the packing forces in the crystal, it also remains unclear whether these drug-induced changes occur in solution, at physiologically active concentrations of monastrol or of other drugs that target this site. We have addressed these issues by using a series of spectroscopic probes to monitor the structural consequences of drug binding. Our results demonstrated that the crystallographic model of an Eg5-ADP-monastrol ternary complex is consistent with several solution-based spectroscopic probes. Furthermore, the kinetics of these spectroscopic signal changes allowed us to determine the temporal sequence of drug-induced structural transitions. These results suggested that L5 may be an element in the pathway that links the state of the nucleotide-binding site to the neck linker in kinesin motors.

Original languageEnglish (US)
Pages (from-to)7977-7982
Number of pages6
JournalJournal of Biological Chemistry
Volume281
Issue number12
DOIs
StatePublished - Mar 24 2006
Externally publishedYes

Fingerprint

Pharmaceutical Preparations
Kinesin
Neck
Adenosine Diphosphate
monastrol
Nucleotides
Binding Sites
Crystals
Molecules
Kinetics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

A pathway of structural changes produced by monastrol binding to Eg5. / Maliga, Zoltan; Xing, Jun; Cheung, Herbert; Juszczak, Laura J.; Friedman, Joel M.; Rosenfeld, Steven.

In: Journal of Biological Chemistry, Vol. 281, No. 12, 24.03.2006, p. 7977-7982.

Research output: Contribution to journalArticle

Maliga, Z, Xing, J, Cheung, H, Juszczak, LJ, Friedman, JM & Rosenfeld, S 2006, 'A pathway of structural changes produced by monastrol binding to Eg5', Journal of Biological Chemistry, vol. 281, no. 12, pp. 7977-7982. https://doi.org/10.1074/jbc.M511955200
Maliga, Zoltan ; Xing, Jun ; Cheung, Herbert ; Juszczak, Laura J. ; Friedman, Joel M. ; Rosenfeld, Steven. / A pathway of structural changes produced by monastrol binding to Eg5. In: Journal of Biological Chemistry. 2006 ; Vol. 281, No. 12. pp. 7977-7982.
@article{a3ea0d570b9a44488b25b26a6d152574,
title = "A pathway of structural changes produced by monastrol binding to Eg5",
abstract = "Monastrol is a small molecule inhibitor that is specific for Eg5, a member of the kinesin 5 family of mitotic motors. Crystallographic models of Eg5 in the presence and absence of monastrol revealed that drug binding produces a variety of structural changes in the motor, including in loop L5 and the neck linker. What is not clear from static crystallographic models, however, is the sequence of structural changes produced by drug binding. Furthermore, because crystallographic structures can be influenced by the packing forces in the crystal, it also remains unclear whether these drug-induced changes occur in solution, at physiologically active concentrations of monastrol or of other drugs that target this site. We have addressed these issues by using a series of spectroscopic probes to monitor the structural consequences of drug binding. Our results demonstrated that the crystallographic model of an Eg5-ADP-monastrol ternary complex is consistent with several solution-based spectroscopic probes. Furthermore, the kinetics of these spectroscopic signal changes allowed us to determine the temporal sequence of drug-induced structural transitions. These results suggested that L5 may be an element in the pathway that links the state of the nucleotide-binding site to the neck linker in kinesin motors.",
author = "Zoltan Maliga and Jun Xing and Herbert Cheung and Juszczak, {Laura J.} and Friedman, {Joel M.} and Steven Rosenfeld",
year = "2006",
month = "3",
day = "24",
doi = "10.1074/jbc.M511955200",
language = "English (US)",
volume = "281",
pages = "7977--7982",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "12",

}

TY - JOUR

T1 - A pathway of structural changes produced by monastrol binding to Eg5

AU - Maliga, Zoltan

AU - Xing, Jun

AU - Cheung, Herbert

AU - Juszczak, Laura J.

AU - Friedman, Joel M.

AU - Rosenfeld, Steven

PY - 2006/3/24

Y1 - 2006/3/24

N2 - Monastrol is a small molecule inhibitor that is specific for Eg5, a member of the kinesin 5 family of mitotic motors. Crystallographic models of Eg5 in the presence and absence of monastrol revealed that drug binding produces a variety of structural changes in the motor, including in loop L5 and the neck linker. What is not clear from static crystallographic models, however, is the sequence of structural changes produced by drug binding. Furthermore, because crystallographic structures can be influenced by the packing forces in the crystal, it also remains unclear whether these drug-induced changes occur in solution, at physiologically active concentrations of monastrol or of other drugs that target this site. We have addressed these issues by using a series of spectroscopic probes to monitor the structural consequences of drug binding. Our results demonstrated that the crystallographic model of an Eg5-ADP-monastrol ternary complex is consistent with several solution-based spectroscopic probes. Furthermore, the kinetics of these spectroscopic signal changes allowed us to determine the temporal sequence of drug-induced structural transitions. These results suggested that L5 may be an element in the pathway that links the state of the nucleotide-binding site to the neck linker in kinesin motors.

AB - Monastrol is a small molecule inhibitor that is specific for Eg5, a member of the kinesin 5 family of mitotic motors. Crystallographic models of Eg5 in the presence and absence of monastrol revealed that drug binding produces a variety of structural changes in the motor, including in loop L5 and the neck linker. What is not clear from static crystallographic models, however, is the sequence of structural changes produced by drug binding. Furthermore, because crystallographic structures can be influenced by the packing forces in the crystal, it also remains unclear whether these drug-induced changes occur in solution, at physiologically active concentrations of monastrol or of other drugs that target this site. We have addressed these issues by using a series of spectroscopic probes to monitor the structural consequences of drug binding. Our results demonstrated that the crystallographic model of an Eg5-ADP-monastrol ternary complex is consistent with several solution-based spectroscopic probes. Furthermore, the kinetics of these spectroscopic signal changes allowed us to determine the temporal sequence of drug-induced structural transitions. These results suggested that L5 may be an element in the pathway that links the state of the nucleotide-binding site to the neck linker in kinesin motors.

UR - http://www.scopus.com/inward/record.url?scp=33646360591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646360591&partnerID=8YFLogxK

U2 - 10.1074/jbc.M511955200

DO - 10.1074/jbc.M511955200

M3 - Article

VL - 281

SP - 7977

EP - 7982

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 12

ER -